TUDRIQEV Is Now Available in the U.S. for Advanced Melanoma
Replimune's TUDRIQEV oncolytic immunotherapy is now commercially available in the U.S. for advanced melanoma, moving the platform into real-world clinical pathways.
Topic
Advanced Melanoma
Topic
Advanced Melanoma
FDA Advisory Committee Backs Melanoma Therapy After Two Rejections
An advanced melanoma therapy that failed twice in prior reviews has won a favorable FDA advisory committee vote, reviving its pat…